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Development of adaptive immunity after COVID-19 and after vaccination against SARS-
CoV-2 is predicated on recognition of viral peptides, presented on HLA class II molecules,
by CD4+ T-cells. We capitalised on extensive high-resolution HLA data on twenty five
human race/ethnic populations to investigate the role of HLA polymorphism on SARS-
CoV-2 immunogenicity at the population and individual level. Within populations, we
identify wide inter-individual variability in predicted peptide presentation from structural,
non-structural and accessory SARS-CoV-2 proteins, according to individual HLA
genotype. However, we find similar potential for anti-SARS-CoV-2 cellular immunity at
the population level suggesting that HLA polymorphism is unlikely to account for observed
disparities in clinical outcomes after COVID-19 among different race/ethnic groups. Our
findings provide important insight on the potential role of HLA polymorphism on
development of protective immunity after SARS-CoV-2 infection and after vaccination
and a firm basis for further experimental studies in this field.
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The new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), responsible for
coronavirus disease 2019 (COVID-19), has caused an ongoing pandemic with 93,805,612
confirmed cases and 2,026,093 deaths worldwide [as of 19 January 2021 (1)]. Several risk factors
for severe COVID-19 are now well-established, including age, gender, obesity and various co-
morbidities such as diabetes, cancer and cardiovascular or chronic lung disease (2–5). There is,
however, an urgent need to better understand the role of race and ethnic differences on health
outcomes. Several studies have highlighted a disproportionate prevalence of COVID-19 infections,
higher rates of hospitalisation, and increased incidence of death in people from black and minority
ethnic groups but the underlying reasons for these observations are not well understood (2, 6–8).org July 2021 | Volume 12 | Article 6693571
Copley et al. HLA Polymorphism and SARS-CoV-2 ImmunityEven after accounting for well-known risk factors, there is still
wide inter-individual clinical variability of COVID-19 outcomes
within considered risk groups, which may reflect underlying genetic
differences (9).The principal genetic region involved in immunity
against viral pathogens is the Major Histocompatibility Complex
encompassing the Human Leukocyte Antigen (HLA) loci. HLA
class I (HLA-A, -B, -C) and HLA class II (HLA-DR, -DQ, -DP)
proteins present viral peptides for recognition by CD8+ and CD4+
T-cells, respectively. The latter orchestrate adaptive anti-viral
immunity and drive B-cell activation and maturation for robust
humoral responses. Extensive polymorphism is observed in the
HLA system, resulting in differences in HLA allele frequency both
within and across human populations. HLA genotype can be a
determining factor in development of protective immunity and, in
turn, may account for part of the observed heterogeneity in
measured immune responses and in clinical outcomes after
SARS-CoV-2 infection (10, 11). It is also well established that
there is marked biological variation in how individuals respond
and maintain immunity after vaccination which is, in part,
attributable to genetic factors (12). It is, therefore, important to
consider the role of HLA polymorphism when designing viral
subunit or peptide vaccine formulations and in assessing
population coverage and likelihood of immune protection after
vaccination (13).
When considering the role of the HLA system in COVID-19
susceptibility and vaccine responses, it is essential to account for
differences in HLA allele frequencies across human populations
and, importantly, for the linkage disequilibrium between HLA
loci that result in population-specific haplotype frequencies.
Here, we utilise information on human HLA haplotype
frequencies of twenty five human populations (four broad
population categories and twenty one detailed population
subcategories) at an unprecedented scale, capitalising on the
extensive high-resolution HLA data deposited in the National
Marrow Donor Program Registry, to compute population level
immune responses against SARS-CoV-2 based on predicted
high-affinity binding of viral proteome derived peptides by
HLA class II molecules. Overall, we find similar potential for
anti-SARS-CoV-2 cellular immunity across all populations
examined suggesting that HLA polymorphism is unlikely to
account for observed disparities in clinical outcomes after
COVID-19 among different race and ethnic groups. However,
within populations, we identify wide variability among
individuals in predicted CD4+ T-cell reactivity against
structural, non-structural, and accessory SARS-CoV-2 proteins,
according to HLA genotype. Nevertheless, we predict robust
immune reactivity against the SARS-CoV-2 Spike protein, the
basis for the majority of current vaccination efforts, both at the
population and at the individual level.MATERIALS AND METHODS
Identification of Potential T-Cell Epitopes
Full viral proteome sequences for SARS-CoV-2 were
downloaded from UniProt (14). FASTA-formatted proteinFrontiers in Immunology | www.frontiersin.org 2sequence data for each protein and protein class were
examined individually and in combination. We produced
potential peptides of 15 amino acids length (15mers), using
sliding windows over the entire proteome. Proteins of fewer
than 15 amino acids in length were not examined. Analyses were
performed considering proteins individually, some protein
domains individually, and in groupings of proteins (both the
whole proteome, and all structural, non-structural, and
accessory proteins).
HLA and Haplotype Frequency
Computation
HLA population frequencies were obtained from US unrelated
stem cell donor registry National Marrow Donor Program
(NMDP)/Be The Match. High resolution HLA Class II
haplotype frequencies (DRB1, DRB3/4/5, DQA1, DQB1, DPA1
and DPB1 loci) were estimated using an expectation-
maximization algorithm [as described by Gragert et al., 2013
(15)] utilising a cohort of 8.9 million US volunteer donors
(NMDP/Be The Match registry snapshot 29/05/2020) HLA
typed by molecular methods (Table S1 showing number of
individuals genotyped). US population categories were
developed based on a race/ethnicity questionnaire included on
the donor consent form. There were four broad population
categories (European American, African American, Asian or
Pacific Islander and Hispanic) and 21 detailed populations
subcategories (African American, African Black, South Asian
Indian, American Indian - South or Central American, Alaska
native of Aleut, North American Indian, Caribbean Black,
Caribbean Hispanic, Caribbean Indian, European Caucasian,
Filipino, Hawaiian or other Pacific Islander, Japanese, Korean,
Middle Eastern or North Coast of Africa, Mexican or Chicano,
Chinese, Hispanic - South or Central American, Black - South or
Central American, Southeast Asian, Vietnamese). Some
individuals were assigned only membership of a broad
population category.
Following Hardy-Weinberg equilibrium proportions, multi-
locus HLA Class II genotypes were generated by randomly
sampling two haplotypes from the same population HLA
haplotype frequency distribution. Simulated genotypes were
generated for each of the four broad and 21 detailed
population groups, with ten replicates at each population of
size 1,000, 5,000 and 10,000.
For population-based analyses at the haplotype level, we
analysed haplotypes up to 99% cumulative coverage within
each population. HLA alleles, when examined individually,
included all HLA alleles present in any of these selected
haplotypes for the four broad and 21 detailed population groups.
Predicted T-Cell Epitope Identification
Peptide binding affinity was assessed for all Class II HLA that
featured in haplotypes in any of the ethnic populations studied
using NetMHCIIpan v4.0 (16). Peptides were examined both for
their predicted binding affinity (nM) and their percentage rank
(compared to a pool of representative peptides for the
corresponding HLA). Peptides were defined as binders if theirJuly 2021 | Volume 12 | Article 669357
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percentage rank was equal to or greater than 2% (default
parameter for strong HLA class II peptide binders). Within the
9,590 15-mer peptides in the entire SARS-CoV-2 proteome,
4,289 peptides were predicted to bind strongly to one or more
HLA Class II molecule. Analyses were also performed using
alternative binding threshold cut-offs of ≤50nM peptide binding
affinity threshold and ≤0.5% percentage rank in combination
with a ≤500nM peptide binding affinity threshold. The
NetMHCIIpan-4.0 programme also identifies the predicted 9-
mer binding core. Of all HLA observed, on average 0.52% of
haplotypes contained an HLA that was not in the list of 5,620
HLA available to run on NetMHCIIpan-4.0. Total predicted
peptide counts for an individual HLA per protein or per whole
proteome were calculated by counting peptides only if they were
both unique to one another (i.e., a unique 15-mer), but also if the
predicted binding core (9-mer) was also unique. This prevented
the count from appearing falsely elevated due to sequential
overlapping peptides which were presenting the same core, by
preventing them from being counted more than once. Total
peptide counts (in the context of an HLA haplotype or genotype)
were also enumerated from peptides with both unique 15-mers
and 9-mer cores, from binding peptides presented in any Class II
HLA within the haplotype or genotype.
Quantification and Statistical Analysis
Peptide-HLA scoring models were assessed using scikit-learn
(17) in Python, specifically using sklearn.metrics.roc_auc_score
(AUROC), sklearn.metrics.average_precision_score (Average
Precision), sklearn.metrics.accuracy_score (Accuracy), and
sklearn.metrics.classification_report (Sensitivity and Specificity)
functions (see Table S3, with n=93 for peptide-HLA
combinations). In order to assess AUROC for two predictor
variables, a composite predictor was calculated consisting of the
normalised sum of both. Population comparisons of peptide
scores were performed by calculating the mean and standard
deviation using NumPy in Python (see Table S4, N=10,000
individuals in simulated population groups). Population
simulations were assessed for normality using statistics.shaipro
(Shapiro-Wilk test) and following demonstration of non-
normality for all distributions examined, with statistics.kruskal
(Kruskal–Wallis one-way analysis of variance) to assess
differences between replicates of population simulations (all
N=10,000), both implemented in Python.RESULTS
Experimental Approach
The principal objective of our study was to examine whether
genetic variation at the HLA loci may influence immune
responses, and therefore COVID-19 clinical outcomes or
response to vaccination, among patients from different ethnic
populations. HLA class II molecules present peptides from
exogenous antigens for CD4+ T-cell recognition and are
therefore critical components for an effective adaptive immuneFrontiers in Immunology | www.frontiersin.org 3response that incorporates humoral (B-cell) and cytotoxic (CD8+
T-cell) arms.
We analysed peptide binding for all classical HLA class II loci
(HLA-DRB1, -DRB3/4/5, -DQA1, -DQB1, and -DPA1, -DPB1).
The main analysis focused on four broad population categories,
African Americans (AFA), European Caucasians (CAU),
Hispanics (HIS) and Asian/Pacific Islanders (API) and sub-
analysis included 21 detailed population subgroups of these
broad categories. To account for linkage disequilibrium
between HLA class II loci, we analysed HLA haplotypes rather
than assuming allele frequencies were independent at each locus.
HLA haplotype frequencies were estimated utilising HLA
genotype data obtained from a cohort of approximately 8.9
million donors (NMDP/Be The Match registry; Table S1). We
analysed a total of 25,128 unique haplotypes to enable 99%
coverage of each population which in turn required the analysis
of 803 HLA class II molecules (see Supplemental Information).
Figure S1 depicts the number of distinct HLA-DRB1, -DRB345
alleles and HLA-DQA1/DQB1, DPA1/DPB1 heterodimers
examined and associated haplotype coverage in each
population. To confirm the robustness of our observations at
the individual level, we analysed multiple replicate genotype
samples and demonstrate with replicate sets of simulated
genotypes of 10,000 individuals that HLA diversity, as
measured by the alpha parameter fits to the power law
distribution, was stable, and the number of unique haplotypes
needed to reach 95% cumulative frequency was also stable across
replicates (Table S6).
Immunogenic T-cell epitopes were identified using the full-
length reference SARS-CoV-2 sequence (18) with 9,744 amino
acids, which was subdivided into the four structural proteins (E,
M, N, and S) and 7 additional open reading frames encoding
non-structural proteins (NSP1-16) and accessory proteins
(proteins 3a, 6, 7a, 7b, 8 and 10). A sliding window of 15
amino acids length was used and, to minimise redundancy,
peptides were only counted towards totals if the HLA class II
binding core was unique. To evaluate peptide binding and stable
display by HLA class II molecules we employed NetMHCIIpan-
4.0 which outputs predicted peptide-HLA binding affinity (IC50)
in nanomolar units and percentile rank of binding affinity
compared to a set of 100,000 random natural peptides. The
percentile rank enables incorporation of information from the
biological antigen presentation pathway in addition to
the peptide-MHC binding event (16, 19). We aimed to detect
strongly binding peptides and, therefore, elected to use a
threshold of ≤2% percentile rank (default parameter for HLA
class II strong peptide binding) combined with an affinity
threshold ≤500nM (16). To further increase the stringency of
criteria for prediction of peptide binding, such that we maximise
precision and reduce the rate of false positive peptides (accepting
we may not recall all possible peptides that could be displayed),
we also explored a model involving a threshold of ≤0.5%
percentage rank and ≤500nM binding affinity. Finally, we
examined a binding affinity threshold of ≤50nM, as previously
suggested (13). To validate the computational models we
analysed publicly available datasets of experimentallyJuly 2021 | Volume 12 | Article 669357
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on the two largest datasets recently described by Snyder et al. (20,
21) and Nolan et al. (22) (250 HLA class II peptides) and by
Mateus et al. (23) (135 HLA class II peptides) that contain
peptides from the entire SARS-CoV-2 proteome. We also
examined two relatively small datasets encompassing 9
nucleocapsid and 25 structural protein-derived (Spike,
nucleocapsid or membrane) peptides (24, 25). In the
aforementioned datasets, the HLA restriction was not known
and validation focused on positive identification of experimental
peptides by the computational models (Supplemental
Information). We also used an HLA-DRB1*04:01 restricted
peptide dataset determined using an in vitro peptide-HLA
stability assay (26). Our analyses showed that scoring peptide
binding based on a combination of ≤2% percentile rank
and ≤500nM binding affinity achieved the best true positive
rate (sensitivity) for predicting experimentally derived SARS-
CoV-2 peptides (Table S2). Similarly, in the HLA restricted
dataset by Prachar et al, the combined ≤2% percentile rank and
≤500nM binding affinity threshold had an AUROC of 0.85 and
provided the best combination of precision and specificity in
classifying stable peptide binders compared to alternative scoring
methods (Table S3A). Finally, we validated our approach using a
recently published dataset of experimentally determined CD4+
T-cell epitopes (27) and demonstrated that our approach does
not introduce systematic bias across the studied populations and
does not over-predict the number of immunogenic epitopes
(Table S3B). It should be noted that using a 50nM threshold,
without accounting for binding characteristics of natural
peptides, resulted in 46% of HLA alleles examined lacking
presentation of any SARS-CoV-2 peptides and a bias towards
HLA-DR as the major SARS-CoV-2 peptide presenting
molecules (Figure S2). Nevertheless, we have confirmed key
aspects of our analyses using both a ≤0.5% percentage rank in
combination with a ≤500nM peptide binding affinity threshold,
and using a ≤50nM peptide binding affinity threshold alone.
Overall, a total of 9,590 15-mer peptides, derived from all 11
SARS-CoV-2 genes, were examined and 4,289 peptides were
predicted to bind strongly according to our defined criteria to at
least one HLA class II molecule.
SARS-CoV-2 Viral Proteome Presentation
at the Molecular HLA Class II Level
We first examined presentation of viral epitopes by all HLA class
II molecules contained in haplotypes representing 99% of the
four major broad ethnic populations. Assessment of presentation
capacity at the entire viral proteome level (Figure 1A) showed
that the majority of HLA class II molecules are capable of
presenting SARS-CoV-2 peptides, albeit with significant
variability. HLA-DR alleles have the highest viral peptide
presentation capacity followed by HLA-DP and, to a
significantly lower extent, HLA-DQ molecules. Notably, certain
common individual HLA molecules were predicted to have very
limited abil i ty to present viral peptides, including
DQA1*03:01~DQB1*02:01 (no peptide presentation from any
protein within the SARS-CoV-2 proteome; with frequency ofFrontiers in Immunology | www.frontiersin.org 43.2% within AFA haplotypes, <0.01% within API haplotypes,
0.1% within CAU haplotypes and 0.5% within HIS haplotypes),
DRB1*03:02 (two peptides presented in total from the entire
proteome; with frequency of 6.3% within AFA haplotypes, 0.01%
within API haplotypes, 0.04% within CAU haplotypes and 1.0%
within HIS haplotypes). Consistent with its known high
immunogenicity (10, 27–31), Spike protein derived peptides
showed strong binding for the majority of HLA class II
molecules although presentation capacity again varied and was
lowest (no peptides presented) for relatively common alleles such
as DQA1*01:01~DQB1*05:03, with a frequency of 1.9-5.4% in
each of the four broad population groups (Figure 1B). This
observation was more prominent for Nucleocapsid derived
peptides where strong binding was predicted to be absent in
117 out of 306 HLA molecules found in 99% of haplotypes in the
four broad ethnic populations (mostly reflecting HLA-DP
molecules and to some extent -DQ molecules; Figure 1C).
Similar findings were noted for the relatively small Membrane
and Envelope structural proteins, with the latter predicted to be
non-immunogenic for the majority of common HLA class II
molecules (Figures 1D, E). For non-structural proteins, HLA
class II presentation capacity was variable and dependent upon
protein amino acid sequence length (data not shown).
SARS-CoV-2 Proteome Immunogenicity at
the Population Level
The capacity of individuals to present viral peptides for
recognition by CD4+ T-cells depends on the composition of
their HLA class II alleles in their inherited haplotypes. Given
variation in population-specific HLA haplotype frequencies, we
hypothesised that potential differences in SARS-CoV-2 proteome
immunogenicity (as reflected by HLA class II peptide
presentation) at the population level may reflect disparities in
capacity for effective anti-SARS-CoV-2 immunity which could in
turn influence response to vaccination or underpin observed
variability in COVID-19 clinical outcomes among different
ethnic populations. To investigate this hypothesis, we
examined viral proteome presentation by HLA class II,
accounting for the distribution of HLA haplotypes in a
population. This analysis showed that the overall capacity for
HLA peptide presentation, at the whole SARS-CoV-2 proteome
level, among the four broad ethnic populations examined was
remarkably similar (Figure 2A). This was also the case
considering T-cell epitopes from each SARS-CoV-2 protein
(Table S4), suggesting that polymorphism at the HLA genomic
region is unlikely to underpin potential differences in immune
responses and, thus, in clinical outcomes among ethnic groups. It
was notable, however, that within ethnic populations the
capacity of individual HLA haplotypes to present viral peptides
varied widely (data on HLA haplotypes examined and SARS-
CoV-2 peptide presentation for the four broad ethnic
populations is provided in Supplemental Information), with
the top 5% of haplotypes predicted to present between 497 and
591 peptides from the entire viral proteome (such as
DRB1*04:01~DRB4*01:01~DQA1*03:01~DQB1*03:01~DPA1*
01:03~DPB1*04:01 which represents 1% of AFA haplotypes,July 2021 | Volume 12 | Article 669357
Copley et al. HLA Polymorphism and SARS-CoV-2 Immunity0.14% of API haplotypes, 3.9% of CAU haplotypes and 0.9% of
HIS haplotypes, predicted to present 506 SARS-CoV-2 peptides)
as opposed to 5% of haplotypes at the opposite end of the
spectrum predicted to present approximately 316 viral peptides
or fewer (e.g. DRB1*03:01~DRB3*01:01~DQA1*05:01~DQB1*
02:01~DPA1*02:01~DPB1*01:01 which represents 0.25% of
AFA haplotypes, 0.02% of API haplotypes, 3.5% of CAU
haplotypes and 1.4% of HIS haplotypes, predicted to present
258 peptides). This observation suggests that individual capacity
to mount CD4+ T-cell immune responses against SARS-CoV-2 isFrontiers in Immunology | www.frontiersin.org 5not uniform and is likely dependent on HLA phenotype. Similar
inter-individual variability was noted for peptide presentation
derived from structural and from non-structural proteins as well
as for distinct SARS-CoV-2 proteins examined (Figures 2B–E
and S3). Recent experimental studies suggested that up to 70% of
CD4+ T-cell responses against SARS-CoV-2 target the Spike,
Membrane and Nucleocapsid antigens (10); our analysis showed
the predicted CD4+ T-cell response to these structural proteins
is highly variable at the haplotype level (Figures 2B–D). In
agreement with the observed immunogenicity of Spike proteinA B
DC
E
FIGURE 1 | SARS-CoV-2 viral proteome presentation at the molecular HLA class II level. The number of viral peptides presented by individual HLA is shown for (A) the
entire SARS-CoV-2 proteome; (B). Spike protein (S protein); (C) Nucleocapsid protein (N protein); (D) Membrane protein (M protein); and (E) Envelope protein (E protein).
The HLA frequency in four broad ethnic populations is shown (AFA, African Americans; API, Asian and Pacific Islanders; CAU, Caucasians; HIS, Hispanics). Bars
are coloured according to HLA locus, as shown. HLA were included in the figure if they had a frequency of ≥ 1% in any haplotype distribution from the four broad
population groups.July 2021 | Volume 12 | Article 669357
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Spike-derived peptides were predicted to be recognised both
within and across ethnic populations (Figure 2B). In contrast,
our analysis suggests that on average 13.9% of HLA haplotypes
within each population have low capacity (≤2 peptides)
to present Nucleocapsid-derived peptides (e.g. DRB1*
0 3 : 0 2 ~DRB 3 * 0 1 : 0 1 ~DQA 1 * 0 4 : 0 1 ~DQB 1 * 0 4 : 0 2
~DPA1*02:02~DPB1*01:01 which presents one peptide, and
accounts for 4.98% of haplotypes found in AFA populations
and 0.44% in HIS populations, although it is rare in API and
CAU populations; Figure 2C). This inter-individual variability
may, in part, account for the heterogeneity in the presence and
magnitude of CD4+ T-cell and antibody responses against the
Nucleocapsid protein noted in recent COVID-19 studies (10, 32,
33). Among non-structural viral proteins, our analysis suggested
NSP3, NSP4 and NSP12 as the most immunogenic, in partFrontiers in Immunology | www.frontiersin.org 6reflecting their size, in each population (Figure S3). The above
noted similarity in overall capacity for SARS-CoV-2 peptide
presentation among different populations was also observed at
different (more stringent) thresholds for HLA-peptide binding,
albeit with even higher individual variability within ethnic
populations (500nM binding affinity and ≤0.5% percentage
rank or ≤50nM binding affinity; Figure S4).
To further explore the consequences of the above
observations at the individual level, and given that every
individual expresses two HLA haplotypes, we generated 10
replicates each of random genotype datasets encompassing
1,000, 5,000 and 10,000 simulated individuals for each
population, as described in the methods. Populations
encompassing 10,000 individuals achieved >95% cumulative
HLA haplotype coverage in every population. As shown in





FIGURE 2 | SARS-CoV-2 derived peptide presentation at the HLA haplotype level. Panels depict SARS-CoV-2 peptide presentation by HLA class II haplotypes
representing 99% of total haplotypes within four broad population groups (African Americans, Asian Pacific Islanders, Caucasians and Hispanics). (A) Whole
Proteome. (B) Spike protein (S protein). (C) Nucleocapsid protein (N protein). (D) Membrane protein (M protein). (E) Envelope protein (E protein). The width of each
step in the curves is proportional to the relative frequency of a specific HLA haplotype.July 2021 | Volume 12 | Article 669357
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ethnic populations, both at the entire viral proteome level and
for individual proteins (Table S4). As noted for the HLA
haplotype analysis, there was wide inter-individual variability
in predicted potential for CD4+ T-cell immune responses,
according to HLA genotype. We noted significant, but variable,
capacity for T-cell reactivity against the entire Spike glycoprotein
across individuals, whereas reactivity against the NucleocapsidFrontiers in Immunology | www.frontiersin.org 7protein was predicted to be weaker for 10% of individuals in each
population, on average (range 7.8-13.3%, as defined by HLA
presentation of less than 5 nucleocapsid peptides). These
observations were confirmed (but, again, inter-individual
variability was higher) using more stringent thresholds for
defining HLA class II peptide presentation (data not shown).
In further analysis, we considered immune reactivity against the






FIGURE 3 | SARS-CoV-2 derived peptide presentation at the HLA genotype level (broad population groups). Panels depict the number of SARS-CoV-2 peptides
presented by individual HLA class II genotypes in simulated populations of 10,000 individuals for four broad population groups (African Americans, Asian Pacific
Islanders, Caucasians and Hispanics). (A) Whole Proteome. (B) Spike protein (S protein). (C). Nucleocapsid protein (N protein). (D) Membrane protein (M protein).
(E) Envelope protein (E protein). (F) Receptor Binding Domain of Spike protein. The width of each step in the curves is proportional to the relative frequency of a
specific HLA genotype. The boxplot charts depict the median, interquartile range (box) and range (whiskers - excluding outliers) for the number of viral peptides
presented at the population level for each of the above ethnic groups.July 2021 | Volume 12 | Article 669357
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currently in clinical trials (34–36). Although, overall, there was
no significant difference in predicted CD4+ T-cell reactivity at the
population level, there were notable differences at the individual
level (both based on HLA haplotype and on genotype analyses)
with wide variation in predicted RBD specific peptide
presentation (Figure 3F). The above analyses were consistent
irrespective of the size of the population sampled and among the
10 replicates at each population size (Kruskal-Wallis test
p-value >0.05 for peptide comparisons at the population level).
We next examined HLA class II presentation of SARS-CoV-2
peptides for a further 21 detailed population subgroups, as
described above (Figure S5 and Table S4). Overall, analysis of
the entire viral proteome identified similar capacity for HLA
class II viral peptide presentation across population subgroups.
This was also the case for structural proteins, including Spike and
RBD, mirroring the findings above for the broad population
groups. Although we did not identify SARS-CoV-2 vulnerability
of particular populations at the HLA level, again we observed
inter-individual variation in predicted cellular immunity within
ethnic groups. This was reflected in the range of predicted viral
peptide presentation within simulated populations of 10,000
individuals including 24-112 for Spike, 4-25 for RBD, 1-24 for
Nucleocapsid and 208-854 for the entire proteome (Table S4).
Immunogenicity Maps of SARS-CoV-2
Proteome at the Population Level
The effectiveness of peptide and subunit vaccine formulations
against SARS-CoV-2 depends on robust presentation by
individual HLA class II molecules and, therefore, investigated
vaccines should account for linkage disequilibrium and HLA
haplotype frequencies in different ethnic populations to achieve
universal coverage. Capitalising on extensive HLA haplotype
frequency data from the NMDP/Be The Match registry, we
generated maps of SARS-CoV-2 immunogenicity for the entire
viral proteome. This analysis showed that each viral protein
contains immunogenic peptide segments with variable degree of
population coverage which is, on the whole, similar across
different populations for a given protein region, as well as
peptide segments of variable length that are non-immunogenic
in any population (Figure 4). Similar observations were made for
coronavirus subunit components that are being investigated as
potential vaccines with several immunogenic peptides predicted
to achieve universal coverage across population groups
(Figure 4). This was particularly evident for the Spike protein
underlying its inherent immunogenicity and its potential as
vaccination target . Table S5 , depicts SARS-CoV-2
immunogenic peptide segments predicted to cover over 90% of
HLA genotypic variation in every broad ethnic group examined.DISCUSSION
Recognition of SARS-CoV-2 peptides in the context of HLA class
II molecules is essential for CD4+ T-cell activation and
proliferation which, in turn, orchestrate the development ofFrontiers in Immunology | www.frontiersin.org 8effector cellular (CD8+ T-cell) and humoral adaptive immune
responses after viral infection and after vaccination. In this
computational study, we investigated the role of HLA on
SARS-CoV-2 immunogenicity at the individual and at the
population level, considering population-specific HLA allele,
haplotype, and genotype frequencies. We accounted for genetic
polymorphism and for HLA linkage disequilibrium in twenty
five ethnic populations by capitalising on, to our knowledge, the
most extensive HLA haplotype frequency information to date to
predict SARS-CoV-2 specific CD4+ T-cell epitopes covering the
entire viral proteome. We find that the overall capacity for anti
SARS-CoV-2 cellular immunity according to HLA class II
genotype is similar at the population level across all ethnic
groups examined. However, we identify wide inter-individual
variability in predicted CD4+ T-cell reactivity against every
SARS-CoV-2 protein according to expressed HLA genotype.
We predict robust immune reactivity against the SARS-CoV-2
Spike protein, the basis for the majority of current vaccination
efforts, both at the population and at the individual level
regardless of population origin. Finally, we provide
c ompr eh en s i v e map s o f SARS -CoV-2 p ro t e ome
immunogenicity accounting for population coverage in
ethnic groups.
Several recent studies have examined the cellular immune
response to SARS-CoV-2 and revealed strong associations
between the T-cell response and COVID-19 severity (29, 37).
Although this relationship is complex to untangle when the
peripheral T-cell repertoire is sampled during the acute phase, it
is notable that SARS-CoV-2 specific CD4+ T-cells have been
associated with lessened COVID-19 severity and that high
frequency of Spike-specific CD4+ T-cell responses were
observed in patients who had recovered from COVID-19 (10,
29, 38, 39). A coordinated and regulated response involving all
branches of adaptive immunity (CD4+, CD8+ and antibody
responses) is likely required to reduce COVID-19 severity,
with the cellular response being key for both initiating the
adaptive response and for controlling the acute infection (29).
Even though neutralising antibody titres are not predictive of
disease severity (29, 40), humoral responses are a key aspect of
protective immunity after infection and critical for generating
sterilising immunity after vaccination (34, 41). In this respect,
current evidence suggests a strong association between the
magnitude of Spike-specific CD4+ T-cells and neutralising
antibody titres (10, 30, 38). Finally, the majority of recent
literature on anti-SARS-CoV-2 immunity indicates there is a
high degree of heterogeneity in the breadth and magnitude of
both humoral and cellular responses to SARS-CoV-2 both at the
individual patient level and in relation to specific viral proteins
(10, 29, 42). Within this context, the observation that patients
with severe COVID-19 had decreased diversity of T-cell
responses suggested that recognition of multiple SARS-CoV-2
T-cell epitopes may be required for development of protective
immunity after infection or after vaccination (43).
The above observations on anti-SARS-CoV-2 cellular
immunity from experimental studies and the role of HLA in
shaping the diversity of the T-cell repertoire (44, 45), place theJuly 2021 | Volume 12 | Article 669357
Copley et al. HLA Polymorphism and SARS-CoV-2 Immunityfindings of our study into context. With regards to susceptibility
to COVID-19, we hypothesised that genetic variation at the HLA
complex may account for observed differences in clinical
outcomes between ethnic groups (2, 46, 47). We performed a
comprehensive analysis of HLA haplotypes and genotypes
covering 99% of genetic HLA variation within twenty five
ethnic populations and showed that the predicted CD4+ T-cell
response is overall remarkably similar at the population level both
looking at the entire SARS-CoV-2 proteome and for individualFrontiers in Immunology | www.frontiersin.org 9viral proteins. This observation is supported by more nuanced
recent investigations which show equivalent COVID-19 clinical
outcomes after adjustment for potential socioeconomic and
clinical confounders (7, 8). We did, however, find significant
inter-individual variability in predicted SARS-CoV-2 proteome
immunogenicity according to HLA phenotype. This variability
was more pronounced for particular viral proteins, such as
nucleocapsid, membrane protein and envelope protein and less




FIGURE 4 | Immunogenicity maps of SARS-CoV-2 proteome at the population level. The panels depict the percentage of HLA class II genotypes, within populations
of 10,000 individuals (AFA, African Americans; API, Asian Pacific Islanders; CAU, Caucasians and HIS, Hispanics), that are predicted to present individual
SARS-CoV-2 peptides from (A). Spike protein (S protein), S1, S2 and Receptor Binding Domain (RBD) are also shown; (B). Nucleocapsid protein (N protein);
(C). Membrane protein (M protein); (D). Envelope protein (E protein); and (E). Open Reading Frame (ORF) 1ab polyprotein.July 2021 | Volume 12 | Article 669357
Copley et al. HLA Polymorphism and SARS-CoV-2 Immunityeven at the lower end of the spectrum, HLA haplotypes were
predicted to present a significant number of CD4+ T-cell epitopes.
Given the relevance of diversity and magnitude of cellular
immunity against SARS-CoV-2, as discussed above, it is
tempting to speculate that HLA phenotype might underpin
some of the observed inter-individual variability in COVID-19
outcomes, along with more established clinical factors. This
might depend on the relative contribution of SARS-CoV-2
proteins to the quality of the immune response. For example,
Grifoni et al. (10) have shown that up to 70% of CD4+ T-cell
responses against SARS-CoV-2 target the Spike, Membrane and
Nucleocapsid antigens whereas significant reactivity was also
noted against nsp3, nsp4 and ORF8. Despite significant
differences between the highest and lowest peptide presenting
HLA haplotypes, we noted substantial numbers of Spike-specific
CD4+ T-cell peptides presented by the majority of HLA
haplotypes in all ethnic groups examined; in comparison, inter-
individual variability according to HLA haplotype was more
pronounced for the remaining of the above, and other, viral
proteins. Whether this observation might translate into
differential clinical outcomes or levels of protective immunity
according to expressed HLA type would need to be examined in
large clinical studies that encompass cohorts representative of the
HLA polymorphism within particular populations. Certainly,
evidence supporting an important role of HLA class II in viral
immunity has been previously reported (48, 49). The current
SARS-CoV-2 pandemic represents a unique opportunity to
address such fundamental questions which have recently
started to be explored (50, 51).
It is also well established that individual response, including
efficacy and relative antibody levels, and maintenance of
immunity after vaccination varies markedly and this biological
variation results from a combination of environmental (such as
age, size, sex, comorbid status, ethnicity, and dose and route of
vaccine administration) and genetic factors (12, 49). Non-
responsiveness affects approximately 2-10% (and up to 20%
following hepatitis B vaccination) of vaccinated healthy
individuals (52, 53). HLA class II haplotype plays a central role
in the presentation of vaccine epitopes and is a known genetic
risk factor for primary vaccination failure (52, 54, 55). Given that
the majority of current vaccination efforts are focused on
generat ing immunity against the Spike prote in of
SARS-CoV-2, we calculated the number of Spike-specific CD4+
T-cell epitopes according to HLA genotype. Our analysis
suggests that immune reactivity against Spike is likely to be
robust both at the population level, including all 25 ethnic groups
examined, and at the individual level. This finding is now
supported experimentally by studies reporting high degree of
seroconversion against Spike after natural infection and after
vaccination (28, 30, 42, 56–61). Nevertheless, we noted inter-
individual variation ranging from 112 peptides for the highest
presenting HLA class II genotypes to 24 for the lowest. Whether
such variation may affect the magnitude and diversity of
protective immunity generated after vaccination requires
further study but it is notable that variation in the degree of
cellular immunity has been reported with a few vaccine
formulations (57, 60, 62). To our knowledge, the relationshipFrontiers in Immunology | www.frontiersin.org 10between HLA genotype, number of vaccine-derived T-cell
epitopes and vaccine responsiveness has not been
systematically examined yet, although this is the focus of
current research efforts in the context of COVID-19.
It is important to acknowledge the limitations of our study.
We used a computational approach to predict SARS-CoV-2
peptides presented by HLA class II molecules, however,
peptide presentation does not always lead to CD4+ T-cell
activation; peptide recognition is complex and incompletely
understood and is influenced by many factors, including
relative expression of individual viral proteins (63).
Nevertheless, NetMHCIIpan-4.0 is an established and validated
algorithm for T-cell epitope prediction that has recently been
updated resulting in improved performance (19). Recent
computational studies investigating SARS-CoV-2 vaccine
immunogenicity have based their approach for T-cell epitope
selection exclusively on peptide-HLA binding affinity
incorporating different thresholds (e.g. 500nM or 50nM) and
identified population coverage gaps in predicted cellular
immunity (13, 64, 65). This approach is affected by inherent
bias of certain HLA molecules towards higher or lower mean
predicted affinities; thus, we show that the 50nM binding affinity
threshold, one of the most commonly used, is heavily biased
towards HLA-DR as the main SARS-CoV-2 peptide presenting
locus with the majority of HLA-DQ and -DP molecules showing
no peptide binding. Accordingly, using a 50nM binding affinity
threshold for defining peptide immunogenicity resulted in very
wide inter-individual variability in predicted CD4+ T-cell
reactivity against SARS-CoV-2 proteins (Figure S4). To
overcome this limitation, we incorporated both binding affinity
prediction and percentile rank, compared to a set of 100,000
random natural peptides, for epitope selection. The rank score
normalizes prediction scores across different HLA molecules and
enables interspecific HLA binding prediction comparisons;
nevertheless, part of the difference in the peptide binding
capacity of HLA molecules (highest for HLA-DR) in this study
may reflect training of NetMHCIIpan-4.0 algorithm on peptide
datasets that contain more information on HLA-DR restricted
peptides. Notwithstanding that currently there is limited
information on experimentally determined SARS-CoV-2
immunogenic T-cell epitopes and even less information on
peptide HLA restriction, we have used available information in
the published literature to validate our approach. We focused on
prediction of strongly HLA binding peptides and demonstrated
that our peptide selection threshold correctly identified the
majority of experimentally determined immunogenic viral
peptides in the largest published datasets (20, 23). We also
aimed to minimise the rate of false positive peptides and
showed, in a limited experimental SARS-CoV-2 peptide dataset
with HLA restrictions published by Prachar et al, that our 500nM
binding affinity and ≤2% rank threshold for peptide selection,
achieves high precision and specificity (1.0 for both). Also,
we confirmed that our observations on SARS-CoV-2
immunogenicity, both in relation to the comparison of
population level responses and in relation to inter-individual
variability, remained valid when we used more stringent peptide
selection criteria (500nM and ≤0.5% rank) and the commonlyJuly 2021 | Volume 12 | Article 669357
Copley et al. HLA Polymorphism and SARS-CoV-2 Immunityused 50nM binding affinity threshold. Finally, we used the
NMDP/Be The Match registry to compute HLA population
frequencies. In terms of population genetics, this study is
limited in that the breadth of HLA diversity of global human
populations is incompletely represented by the US population
categories, and sampling depth varied widely among those
categories included. However, the accuracy of US population
HLA frequency estimates has been validated in multiple practical
settings in transplantation, and HLA frequencies from many
global population datasets from other stem cell registries often
have high similarity with US population estimates (66–68).
In conclusion, we present a rigorous immune-informatics
approach to evaluate the potential for cellular immunity against
SARS-CoV-2 at the population and at the individual level
capitalising on, to our knowledge, the most comprehensive
assessment of HLA genetic variation to date. Our findings
provide important insight on the potential role of HLA
polymorphism on development of protective immunity after
SARS-CoV-2 infection and after vaccination and a firm basis
for further experimental studies in this field.DATA AVAILABILITY STATEMENT
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